NCT04217954已完成2 期
Hepatic Arterial Infusion Chemotherapy With Oxaliplatin, 5-fluorouracil and Bevacizumab Plus Intravenous Toripalimab for Advanced Biliary Tract Cancer
Peking University1 个研究点 分布在 1 个国家目标入组 32 人开始时间: 2020年7月28日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 32
- 试验地点
- 1
- 主要终点
- Overall response rate
研究概览
简要总结
Hepatic arterial infusion chemotherapy (HAIC) deliver high concentration of chemotherapeutic agents directly to the liver tumor, was proved to be effective for intrahepatic and perihilar cholangiocarcinoma. Based on the potential synergistic effect of bevacizumab, chemotherapy and PD-1 inhibitor, this phase II clinical study want to test the efficacy and safety using intra-arterial infusion of oxaliplatin, 5-fluorouracil and bevacizumab combined with intravenous infusion of PD-1 inhibitor (Toripalimab) in the treatment of unresectable biliary malignant tumors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Biliary tract cancer proved by histology or cytology
- •Metastatic advanced or locally advanced unresectable biliary tract cancer, including gallbladder cancer, intrahepatic cholangiocarcinoma and perihilar cholangiocarcinoma, decided by hepatobiliary doctor and radiologist.
- •At least one measurable lesion within liver;
- •No prior intra-arterial/systemic chemotherapy or other systemic therapies
- •Prior resection, TACE or ablation will be allowed.
- •Age from 18 years old to 80 years old.
- •the performance of Eastern Cooperative Oncology Group (ECOG) <2
- •Child-Pugh A or Child-Pugh B (≤ score 7).
- •Expectant survival time ≥ 3 months.
- •Baseline blood count test and blood biochemical must meet following criteria:
- •Hemoglobin ≥ 90 g/L;
- •Absolute neutrophil count ≥ 1.5×10^9/L;
- •Blood platelet count ≥ 100×10^9/L;
- •Alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤ 2.5 times of upper limit of normal (ULN);
- •Total bilirubin ≤ 2 times of ULN;
- •Serum creatinine ≤ 1.5 times of ULN;
- •Albumin ≥ 30 g/L.
- •Patients sign informed consent.
排除标准
- •Distal cholangiocarcinoma.
- •Allergic to contrast agent.
- •Pregnant or lactational.
- •Allergic to 5-fluorouracil, or have metabolic disorder of 5-fluorouracil.
- •More than 80 years old.
- •Previous systematic chemotherapy or radiotherapy.
- •Child-Pugh C or Child-Pugh B (≥ score 8).
- •Coinstantaneous a lot of malignant hydrothorax or ascites.
- •History of organ transplantation (including bone marrow auto-transplantation and peripheral stem cell transplantation).
- •Coinstantaneous infection and need anti-infection therapy.
- •Hepatitis B virus DNA load ≥ 100 IU/ml (patients whose hepatitis B virus DNA load decreased to < 100 IU/ml after anti-virus therapy could be enrolled).
- •Coinstantaneous peripheral nervous system disorder or with history of obvious mental disorder and central nervous system disorder.
- •Diagnosed other kinds of malignant within 5 years, except for non-melanoma skin cancer and carcinoma in situ of cervix.
- •Without legal capacity.
- •Impact the study because of medical or ethical reasons.
- •Uncorrectable coagulation disorder.
- •Obvious abnormal in ECG or obvious clinical symptoms of heart disease, like congestive heart failure (CHF), coronary heart disease with obvious clinical symptoms, unmanageable arrhythmia and hypertension.
- •History of myocardial infarction within 12 months, or Grade III/IV of heart function.
- •Severe liver disease (like cirrhosis), renal disease, respiratory disease, unmanageable diabetes or other kinds of systematic disease.
研究组 & 干预措施
OXA, 5-FU and Bev plus Toripalimab
Experimental
the patients enrolled in this arm would receive hepatic arterial infusion chemotherapy with oxaliplatin, 5-fluorouracil and bevacizumab plus intravenous Toripalimab
干预措施: OXA, 5-FU and bevacizumab plus Toripalimab (Drug)
结局指标
主要结局
Overall response rate
时间窗: From the start of treatment until the end of treatment, up to approximately 3 years
CR plus PR according to imRECIST
次要结局
- Progression-free survival(From the start of the treatment until first documented progression or death from any cause, whichever came first, assessed up to approximately 3 yearsse date of disease progression)
- Overall survival(From the start of treatment until death or lost to follow-up, up to approximately 3 years)
- Adverse events(From the start of treatment until the end of treatment, up to approximately 3 years)
研究者
Xiaodong Wang, MD
Professor
Peking University
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
HAIC of FOLFOX Plus Sorafenib vs HAIC of FOLFIRINOX Plus Sorafenib for Advcanced HCCHepatocellular CarcinomaNCT03812783Sun Yat-sen University100
招募中
3 期
HAIC With FOLFOX Versus Systemic Chemotherapy With GP for Unresectable ICCIntrahepatic CholangiocarcinomaNCT04961970Shi Ming188
Approved For Marketing
不适用
HAIC Using Oxaliplatin Plus Fluorouracil/Leucovorin for Patients With Locally Advanced HCCHepatocellular CarcinomaBlood Vessel, Hepatic, Artery InjuryNCT02436044Ming Zhao
撤回
1 期
Hepatic Artery Infusion With OxaliplatinMetastasisColorectal CancerLiver CancerNCT00244348Medical College of Wisconsin
招募中
3 期
HAIC With One-day FOLFOX vs. HAIC With Two-day FOLFOX for Unresectable HCC: a Non-inferiority StudyHepatocellular CarcinomaNCT05476432Sun Yat-sen University300